Regulatory T Cell Expansion at 33°C for Stable FoxP3 Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for in vitro expansion of regulatory T cells (Tregs) face challenges in maintaining high FoxP3 expression and suppressor activity over time, leading to reduced efficacy in clinical therapies due to low proliferative potential and increased production of proinflammatory cytokines.

Innovation Solution

Culturing Tregs at a temperature below 37°C, specifically at 33°C, to maintain high FoxP3 expression and prevent TSDR methylation, resulting in a several-fold increase in Treg numbers with stable suppressor activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If Tregs are cultured at standard temperature (37°C) to achieve extensive proliferation, then the number of Tregs increases, but FoxP3 expression significantly declines and suppressor activity is lost

Engineering Contradiction:
Improvenumber of TregsVSAvoidFoxP3 expression
Core Design Contradiction:
Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The patent applies parameter changes by culturing Tregs at a reduced temperature of 33°C instead of the standard 37°C. This temperature modification creates an optimal balance that allows extensive Treg proliferation while maintaining stable and high FoxP3 expression levels throughout the culture period, thereby preserving suppressor activity

Inventive Principle:
Principle #35Parameter changes

2Productivity

If Tregs are cultured at 37°C to maximize proliferation speed, then the culture duration is shortened, but TSDR methylation increases and suppressor activity decreases

Engineering Contradiction:
Improveproliferation speedVSAvoidTSDR methylation
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent implements parameter changes by reducing the culture temperature to 33°C, which slows the proliferation rate just enough to prevent TSDR methylation while still achieving substantial Treg expansion within a clinically relevant timeframe

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If Tregs are extensively proliferated in vitro, then the therapeutic dose is sufficient, but the cells lose their characteristic Treg phenotype and acquire proinflammatory properties

Engineering Contradiction:
Improvetherapeutic doseVSAvoidTreg phenotype stability
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent uses parameter changes (culturing at 33°C) to enable extensive Treg proliferation while maintaining phenotype stability. This temperature optimization ensures that even after multiple passages and extensive expansion, Tregs retain their characteristic regulatory phenotype and suppressor activity without acquiring proinflammatory properties

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP3402877B1Method for ex vivo expansion of regulatory t cells
Publication Date: 2025.11.26 GDANSKI UNIV MEDYCZNY
  • EP3402877B1 patent drawingFigure 1~2D
  • EP3402877B1 patent drawingFigure 3
  • EP3402877B1 patent drawingFigure 4A~4E

AI summary

The invention relates to a new method for in vitro expansion of CD4+CD25HighCD127- /lowFoxP3+ Tregs, wherein: - The process of Treg expansion takes place permanently or temporarily at a temperature below 37°C, optimally at a temperature of 33°C. - The isolated Tregs are expanded in SCGM or X-vivo-20 medium supplemented with human serum or with foetal bovine serum. - Magnetic beads coated with anti-CD3 and anti-CD28 antibodies at 1:1 [cell: bead) ratio and interleukin-2 are added to the culture.